AngioDynamics to buy electroporation tumour ablation firm Oncobionic
This article was originally published in Clinica
AngioDynamics has signed a deal to acquire Oncobionic, a firm developing electroporation technology to treat tumours, for up to $25m. The two companies became partners in 2004.
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.